Monte Rosa Therapeutics Inc (GLUE) saw a significant price increase of 46.60% in pre-market trading, with the stock crossing above the 20-day SMA. This surge is attributed to the announcement of MRT-8102's interim results, which demonstrated an 85% reduction in inflammation for patients at high cardiovascular disease risk, showcasing its potential effectiveness.
The positive movement aligns with broader market weakness, as the Nasdaq-100 is down 0.15% and the S&P 500 is down 0.04%. Despite this, the strong clinical results from MRT-8102 have attracted investor interest, indicating a sector rotation towards biotech stocks amid the overall market decline.
The implications of these results are significant for Monte Rosa, as they not only highlight the potential of MRT-8102 in treating cardiovascular diseases but also reinforce the company's position in the biotechnology sector. The upcoming Phase 2 study planned for 2026 could further enhance investor confidence and drive future growth.
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 30.40 USD with a low forecast of 20.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 30.40 USD with a low forecast of 20.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.130
Low
20.00
Averages
30.40
High
37.00
Current: 21.130
Low
20.00
Averages
30.40
High
37.00
Wells Fargo
Equal Weight -> Overweight
upgrade
$22
2025-12-16
Reason
Wells Fargo
Price Target
$22
AI Analysis
2025-12-16
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target. The firm cites the company's catalyst path in 2026 for the upgrade. Wells sees upside from MRT-8102's Phase 1 update in the first half of 2026 and likely disclosure of Novartis' (NVS) plans for MRT-6160. The MRT-8102 Phase 1 update should be "de-risking," the analyst tells investors in a research note.
Wedbush
Robert Driscoll
Buy
Maintains
$15 → $17
2025-03-21
Reason
Wedbush
Robert Driscoll
Price Target
$15 → $17
2025-03-21
Maintains
Buy
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLUE
Unlock Now
Wells Fargo
Derek Archila
Hold
Maintains
$11 → $10
2025-03-21
Reason
Wells Fargo
Derek Archila
Price Target
$11 → $10
2025-03-21
Maintains
Hold
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
